biote Corp. BTMD
1.04 USD -0.05 (-4.59%)
Nov 12, 2026, 3:16 PM EST
1.02 Day range 1.11
0.99 52-week range 2.90
- YTD
- -60.00%
- 1 year
- -60.61%
News
seekingalpha.com biote Corp. (BTMD) Q3 2026 Earnings Call Transcript biote Corp. ( BTMD ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Robert Peterson - Interim CEO, CFO & Chief Business Officer Conference Call Participants Szymon Serowiecki…
benzinga.com Biote Q3 2026 Earnings Call Transcript Biote (NASDAQ:BTMD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…
benzinga.com B. Riley Securities Maintains Neutral on Biote, Lowers Price Target to $1.5 B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $2 to $1.5.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
benzinga.com Biote Q2 EPS $(0.23) Misses $0.04 Estimate, Sales $44.232M Miss $46.148M Estimate Biote (NASDAQ:BTMD) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $0.04 by 675 percent. This is a 330 percent decrease over earnings of $0.10 per share…
benzinga.com Biote Reaffirms FY26 Guidance For Revenue Above $190M And Adjusted EBITDA Above $38M Biote reaffirmed its full year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of this year.
benzinga.com Biote Appoints CFO And Chief Business Officer Bob Peterson As Interim CEO And Director, Effective June 8; Bret Christensen Steps Down As CEO Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief…- benzinga.com Biote Q1 2026 Earnings Call: Complete Transcript
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Biote Q1 EPS $0.06 Beats $0.03 Estimate, Sales $44.935M Miss $46.023M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 83.78 percent decrease over earnings of $0.37 per share…- benzinga.com Truist Securities Maintains Buy on Biote, Lowers Price Target to $4 Truist Securities analyst Gregory Fraser maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $5 to $4.
- benzinga.com B. Riley Securities Maintains Neutral on Biote, Lowers Price Target to $2 B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $3 to $2.
benzinga.com Biote Q4 EPS $0.06 Beats $0.05 Estimate, Sales $46.408M Beat $46.190M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 40 percent decrease over earnings of $0.10 per share…- benzinga.com Earnings Scheduled For March 11, 2026
benzinga.com Earnings Outlook For Biote - benzinga.com Biote Expects $1.3M Charge For Q4 Due To Recall Of Specific Lots Of Hormone Pellets; Additional Recall Costs In 2026 Estimated At $1.0M On January 26, 2026, F.H. Investments, Inc. ("Asteria Health"), a 503B manufacturer of compounded bioidentical hormones and wholly-owned subsidiary of biote Corp. (the "Company"), out of an abundance…
- benzinga.com Biote Affirms FY2025 Sales Guidance of $190.000M vs $192.670M Est Biote (NASDAQ:BTMD) affirms FY2025 sales outlook from $190.000 million to $190.000 million vs $192.670 million estimate.
- benzinga.com Biote Q3 EPS $0.22 Beats $0.07 Estimate, Sales $47.956M Beat $47.757M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.07 by 214.29 percent. This is a 33.33 percent decrease over earnings of $0.33 per…
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com B. Riley Securities Downgrades Biote to Neutral, Lowers Price Target to $4 B. Riley Securities analyst Jeff Van Sinderen downgrades Biote (NASDAQ:BTMD) from Buy to Neutral and lowers the price target from $8 to $4.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com Biote Lowers FY2025 Sales Guidance from $202.000M-$208.000M to $190.000M vs $204.667M Est Biote (NASDAQ:BTMD) lowers FY2025 sales outlook from $202.000 million-$208.000 million to $190.000 million vs $204.667 million estimate.
- benzinga.com Biote Q2 EPS $0.10 Beats $0.06 Estimate, Sales $48.90M Miss $49.52M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.06 by 58.73 percent. This is a 152.63 percent increase over losses of $(0.19) per…
- benzinga.com Earnings Scheduled For August 6, 2025
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Biote Affirms FY2025 Sales Guidance of $202.00M-$208.00M vs $205.31M Est Biote (NASDAQ:BTMD) affirms FY2025 sales outlook from $202.00 million-$208.00 million to $202.00 million-$208.00 million vs $205.31 million estimate.
benzinga.com Biote Q1 EPS $0.37 Beats $0.07 Estimate, Sales $48.99M Beat $46.99M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.07 by 428.57 percent. This is a 716.67 percent increase over losses of $(0.06) per…- benzinga.com Earnings Scheduled For May 7, 2025
benzinga.com Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Biote Sees FY25 Revenue $202M-$208M Vs $227.18M Est.; Adj. EBITDA $59M-$64M The Company expects the following for fiscal 2025:($ in millions)2025 Guidance Ranges Revenue$202-$208Adjusted EBITDA2$59-642025 Procedure revenue is expected to increase approximately 2-4% from…
- benzinga.com Biote Q4 2024 GAAP EPS $0.10, Inline, Sales $49.834M Miss $51.245M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. This is a 44.44 percent decrease over earnings of $0.18 per share from the same period…
- benzinga.com Craig-Hallum Maintains Buy on Biote, Lowers Price Target to $8 Craig-Hallum analyst Alex Fuhrman maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $12 to $8.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For March 12, 2025
- benzinga.com Biote Announces Terry Weber Retiring As CEO And Director And Transitioning To Strategic Advisor To Company's Board Of Directors; Bret Christensen To Succeed As CEO And Director, Effective February 1, 2025. Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of DirectorsHealth Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Directorbiote…
benzinga.com Craig-Hallum Initiates Coverage On Biote with Buy Rating, Announces Price Target of $12 Craig-Hallum analyst Alex Fuhrman initiates coverage on Biote (NASDAQ:BTMD) with a Buy rating and announces Price Target of $12.- benzinga.com Biote Lowers FY2024 Sales Guidance from $200.00M-204.00M to $197.00M-$201.00M Biote (NASDAQ:BTMD) lowers FY2024 sales outlook from $200.00 million-204.00 million to $197.00 million-201.00 million.
- benzinga.com Biote Q3 EPS $0.33 Beats $0.09 Estimate, Sales $51.38M Inline Biote (NASDAQ:BTMD) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.09 by 266.67 percent. This is a 37.5 percent increase over earnings of $0.24 per…
- benzinga.com Earnings Scheduled For November 12, 2024
- benzinga.com Biote Reiterates 2024 Financial Guidance Of $200M - $204M, Est $202.049M The company said, "Based on our solid first half performance and our expectation for accelerated growth in the second half of the year, we reiterate our 2024 financial guidance for revenue and…
- benzinga.com Biote Q2 2024 GAAP EPS $(0.19) Misses $0.09 Estimate, Sales $49.169M Beat $49.062M Estimate Biote (NASDAQ:BTMD) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $0.09 by 311.11 percent. This is a 24 percent increase over losses of $(0.25) per…
- benzinga.com Biote Signs Binding Term Sheet With Stockholder Marci M. Donovitz To Resolve Litigation; Enters $60M Agreement To Repurchase 8.3M Shares and Cancel 4.0M Earnout Shares For $60 million in the aggregate, Biote will repurchase all of the approximately 8.3 million of the Paired Interests and/or Class A Shares, as applicable, owned by Ms. Donovitz and will release and…
- benzinga.com Biote Reiterates Guidance 2024 Financial Outlook"Based on our solid first quarter financial performance and our expectations for stronger revenue growth in the second half of the year, we reaffirm our 2024 financial…
- benzinga.com Biote Q1 2024 GAAP EPS $(0.06) Misses $0.03 Estimate, Sales $46.804M Beat $45.711M Estimate Biote (NASDAQ:BTMD) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.03 by 300 percent. This is a 84.62 percent increase over losses of $(0.39) per…
- benzinga.com Biote Announces Definitive Settlement With Founder, Company To Repurchase All Of Founder's 18.4M Shares At $4.17 Per Share Company to repurchase all of Founder's 18.4 million shares at $4.17 per sharebiote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the…